- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination with Atezolizumab and Obinutuzumab in Richter Transformation of CLL
This study is testing a new combination of medicines (Venclexta, Tecentriq, and Gazyvaro) for adults with Richter Transformation, a type of aggressive cancer linked to chronic lymphocytic leukemia (CLL). Doctors want to see if this treatment is safe and helps shrink the cancer.
For: Richter syndrome of chronic lymphocytic leukemiaItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients with CLL and Coexisting Medical Conditions
For: Chronic Lymphocytic Leukemia (CLL)Bulgaria · Estonia · Romania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Prospective, Open-Label, Multicenter Randomized Phase III Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine and Rituximab (BR) in FIT Patients with previously untreated Chronic Lymphocytic Leukemia (CLL) without DEL(17P) or TP53 Mutation
For: Chronic Lymphocytic Leukemia (CLL)Spain · France · Italy